Chart Review of Patients Undergoing Ketamine Infusions

CompletedOBSERVATIONAL
Enrollment

891

Participants

Timeline

Start Date

December 3, 2019

Primary Completion Date

September 14, 2023

Study Completion Date

September 14, 2023

Conditions
Major Depressive DisorderBipolar DisorderObsessive-Compulsive DisorderPost Traumatic Stress Disorder
Interventions
DRUG

Ketamine Hydrochloride

Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.

Trial Locations (1)

L5C 4E7

Canadian Rapid Treatment Centre of Excellence, Mississauga

All Listed Sponsors
lead

Brain and Cognition Discovery Foundation

OTHER

NCT04209296 - Chart Review of Patients Undergoing Ketamine Infusions | Biotech Hunter | Biotech Hunter